• 1
    Faderl S,Kantarjian H. Novel therapies for myelodysplastic syndromes. Cancer. 2004; 101: 226241.
  • 2
    Faderl S,Kantarjian H. Myelodysplastic syndromes. In: DeVitaV, HellmanS, RosenbergS, eds. Cancer: Principles and Practice of Oncology.7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005: 21442154.
  • 3
    Bennett JM,Catovsky D,Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982; 51: 189199.
  • 4
    Harris NJ,Jaffe ES,Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1977. J Clin Oncol. 1999; 17: 38353849.
  • 5
    Greenberg P,Cox C,LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89: 20792088.
  • 6
    Gatto S,Ball G,Onida F,Kantarjian HM,Estey EH,Beran M. Contribution of beta-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS). Blood. 2003; 102: 16221625.
  • 7
    Kantarjian H,Beran M,Cortes J, et al. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Cancer. 2006; 106: 10991109.
  • 8
    Sierra J,Perez WS,Rozman C, et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood. 2002; 200: 19972004.
  • 9
    Cutler CS,Lee SJ,Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004; 104: 579585.
  • 10
    Silverman LR,Demakos EP,Peterson BL, et al. Randomized controlled trial of azacytidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002; 20: 24292440.
  • 11
    Kantarjian H,Issa JP,Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006; 106: 17941780.
  • 12
    Kantarjian H,Oki Y,Garcia-Manero G, et al. Results of a randomized study of three schedules of low-dose decitabine in higher risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007; 109: 5257.
  • 13
    Berry DA. Bayesian clinical trials. Nat Rev Drug Discov. 2006; 5: 2736.
  • 14
    Cheson BD,Bennett JM,Kantarjian H, et al. Report of an International Working Group to standardize response criteria for myelodysplastic syndromes. Blood. 2000; 96: 36713674.
  • 15
    Cheson BD,Greenberg PL,Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006; 108: 419425.
  • 16
    Cheson BD,Bennett JM,Kopecky KJ, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003; 21: 46424649.